Society for Neuro-Oncology Annual Meeting | Conference

Dr. Heimberger on FGL2 as a Regulator of Tumor-Mediated Immune Suppression

November 21st 2015

Amy B. Heimberger, MD, discusses the potential of FGL2 as a multi-modality regulator of tumor-mediated immune suppression in patients with glioblastoma.

Promising Subgroup Data Leads to Phase III Immunotherapy Study for GBM

November 21st 2015

Findings from a subgroup of patients enrolled in a phase II study assessing the dendritic vaccine ICT-107 for patients with HLA-A2+ glioblastoma multiforme merit further exploration in a phase III study.

June Provides Insight Into Managing AEs From CAR T-Cell Therapies

November 21st 2015

Though clinical work is ongoing and early, researchers are already considering how to manage potentially fatal neurotoxicities in patients treated with chimeric antigen receptor T-cell therapy

Dr. Sampson on Nivolumab Monotherapy for Recurrent Glioblastoma

November 20th 2015

John H. Sampson, MD, PhD, MBA, MHSc, discusses results from cohort 1 of the CHECKMATE-143 trial.

Immune Checkpoint Inhibitors Hold Promise In Glioblastoma

November 20th 2015

There are reasons to suggest that immune checkpoint inhibitors may be successful against central nervous system tumors, including glioblastoma.

Second-Line Optune Improves Survival in GBM

November 20th 2015

The addition of Optune to chemotherapy and/or bevacizumab improved survival in patients with recurrent glioblastoma multiforme.

Dr. Reardon on Updated Data From the Phase II ReACT Trial

November 20th 2015

David Reardon, MD, discusses updated survival findings from the phase II ReACT trial, which analyzed rindopepimut (CDX-110) plus bevacizumab for the treatment of relapsed glioblastoma.

Testing Checkpoint Inhibitors in Brain Cancer Requires Careful AE Management

November 20th 2015

As immunotherapy begins to be studied across central nervous system tumors it becomes increasingly important for practitioners to understanding the unique adverse event profiles associated with these agents.

Experts Discuss Immunotherapy's Potential in Neuro-Oncology

November 17th 2014

Immunotherapy's promise as well as its challenges as a treatment for patients with brain cancer was the focus of a plenary session held November 15 at the Society of Neuro-Oncology's (SNO) 2014 Annual Meeting in Miami Beach.

Dr. Raizer Discusses Proton Therapy for Glioma

November 17th 2014

Jeffrey J. Raizer, MD, Co-Director, Northwestern Brain Tumor Institute, Professor in Neurology, Ken and Ruth Davee Department, Medicine-Hematology/Oncology, Northwestern University Feinberg School of Medicine, discusses a study that analyzed the overall survival and toxicity of proton therapy for large-volume re-irradiation for recurrent glioma.

Oncolytic Virus Shows Early Promise in Glioma

November 17th 2014

The oncolytic virus Delta-24-RGD can infect, replicate, and kill glioma cells in patients, according to phase I research presented at the 2014 Society for Neuro-Oncology (SNO) Annual Meeting in Miami.

Dr. de Groot Discusses Altiratinib as Potential Treatment for Glioblastoma

November 17th 2014

John F de Groot, MD, nuro-oncologist, MD Anderson Cancer Center, discusses the efficacy of the novel c-MET inhibitor altiratinib in glioblastoma.

Dr. Stupp Discusses NovoTTF With Temozolomide in Glioblastoma

November 16th 2014

Roger Stupp, MD, Professor of Oncology, University of Zürich; Chairman, Department of Oncology and Cancer Center, University of Zürich Hospital, Zürich, Switzerland, discusses the interim analysis of the EF-14 trial, which compared NovoTTF-100A together with temozolomide versus temozolomide alone in patients with newly diagnosed glioblastoma multiforme (GBM).

Survival Improvement With NovoTTF Leads to Early End of Phase III Trial

November 16th 2014

Use of the NovoTTF system along with adjuvant temozolomide led to longer progression-free survival and overall survival in patients with glioblastoma.

Dr. Butowski Discusses Dianhydrogalactitol in Patients with Recurrent GBM

November 16th 2014

Nicholas Butowski, MD, associate professor, University of California, San Francisco, neuro-oncologist, UCSF Medical Center, discusses a phase I/II study of dianhydrogalacitol in patients with recurrent glioblastoma multiforme (GBM).

Rindopepimut Leads to Improved PFS in Compassionate Use Study

November 16th 2014

The vaccine rindopepimut appears to help PFS and OS in patients with epidermal growth factor receptor variant III mutation in glioblastoma-a patient group with traditionally poor outcomes.

Dr. van den Bent Discusses Bevacizumab Plus Lomustine in Recurrent Glioblastoma

November 15th 2014

Martin J. van den Bent, MD, professor, Neuro-Oncology, Erasmus MC-Daniel den Hoed Cancer Center, Rotterdam, the Netherlands, discusses the BELOB trial, which examined bevacizumab versus bevacizumab plus lomustine versus lomustine single agent in recurrent glioblastoma.

Ceritinib Effective in Patients With Brain Metastases

November 15th 2014

The next-generation ALK inhibitor ceritinib showed clinically significant antitumor activity in patients with ALK-rearranged NSCLC, including those with brain metastases.

Dr. Reardon Discusses Rindopepimut Plus Bevacizumab in Glioblastoma

November 15th 2014

David Reardon, MD, clinical director, Center for Neuro-Oncology, Dana-Farber Cancer Institute, president, Society for Neuro-Oncology, discusses the ReACT study, which examined the rindopepimut vaccine (CDX-110) plus bevacizumab in patients with relapsed glioblastoma.

Rindopepimut Plus Bevacizumab Shows Prolonged Survival in Recurrent Glioblastoma

November 15th 2014

The vaccine rindopepimut plus bevacizumab induced tumor regression in a subset of patients with recurrent glioblastoma.

NEXT PAGE
PREVIOUS PAGE
x